Multiple myeloma (MM) treatment has changed tremendously, with significant improvement in patient out-comes. One group with a suboptimal benefit is patients with high-risk cytogenetics, as tested by ...
Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...
A DNA index cutoff ≥1.10 delivered excellent discrimination for HHD (AUC 0.947) with high sensitivity and near-rule-out performance when negative (NPV 99.1%). Karyotype failure occurred in 25.2%, and ...
Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results